Krystal Biotech
KRYS
324.57
-2.24
-0.69%
Krystal Biotech
US · KRYS
#1515 by market cap
Listed 2017
324.57
-2.24
-0.69%
Live - 5344 symbols - heartbeat 478s ago
· 2026-10-08 05:56
Pre-market
324.57
0.00%
After-hours
324.57
0.00%
- Market cap
- 9.61B
- P/E (TTM)i
- 40.67
- P/Bi
- 7.07
- EPSi
- 6.84
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on KRYS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 101.94% -0.04pp
- Institutions
- 508 +3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund76.34%
Hedge Fund17.23%
Individual/Insider9.94%
Public Company2.63%
VC/PE Fund2.15%
Private Company1.14%
Government Pension Fund1.06%
Sovereign Wealth Fund0.89%
Insurance Company0.26%
Top holders as of 2026-06-30
FMR
14.93% · 4.42M sh
BlackRock
14.13% · 4.18M sh
Avoro Capital Advisors LLC
9.76% · 2.89M sh
Vanguard Portfolio Management, LLC
5.32% · 1.57M sh
Suma Krishnan
4.88% · 1.44M sh
Vanguard Capital Management, LLC
4.83% · 1.43M sh
Krish Krishnan
4.82% · 1.43M sh
State Street Global Advisors
4.56% · 1.35M sh
Soleus Capital Management, L.P.
3.17% · 939.25K sh
Capital Research
2.63% · 777.84K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Suma Krishnan | Founder, COO, President of R&D and Director | 4.88% |
| Krish Krishnan | Chairperson & CEO | 4.82% |
| Dino Rossi | Independent Director | 0.17% |
| Kathryn Romano | Chief Accounting Officer | 0.08% |
| Laurent Goux | Senior VP & GM of Europe | 0.00% |
| Daniel Janney | Lead Independent Director | -- |
| Julian Gangolli | Independent Director | -- |
| E. Sutherland | Independent Director | -- |
| Alta Bioequities | -- | -- |
| Christopher Mason | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-13 | Daniel Janney | Lead Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Daniel Janney | Lead Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Dino Rossi | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Dino Rossi | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Julian Gangolli | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Julian Gangolli | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | E. Sutherland | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | E. Sutherland | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Christopher Mason | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Christopher Mason | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-13 | Catherine Mazzacco | Independent Director | Other Derivative Acquisition | +471 | -- |
| 2026-09-13 | Catherine Mazzacco | Independent Director | Other Derivative Acquisition | +1,187 | $340.03 |
| 2026-09-03 | Krish Krishnan | Chairperson & CEO | Automatic Disposition | -520 | $354.54 |
| 2026-09-03 | Krish Krishnan | Chairperson & CEO | Open Market Disposition | -24,480 | $355.57–366.56 |
| 2026-09-03 | Suma Krishnan | Founder, COO, President of R&D and Director | Automatic Disposition | -520 | $354.54 |
| 2026-09-03 | Suma Krishnan | Founder, COO, President of R&D and Director | Open Market Disposition | -24,480 | $355.57–366.56 |
| 2026-08-13 | Dino Rossi | Independent Director | Other Disposition | -3,691 | -- |
| 2026-08-13 | Dino Rossi | Independent Director | Open Market Disposition | -25,000 | $325.60–333.23 |
| 2026-06-24 | John Thomas | General Counsel | Derivative Exercise and Sale | -1,000 | $179.25–347.27 |
| 2026-06-03 | Krish Krishnan | Chairperson & CEO | Automatic Disposition | -320 | $300.75 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:56:28 · For reference only, not investment advice and not tailored to your situation.